logo
Share SHARE
FONT-SIZE Plus   Neg

Optimer's DIFICID Benefits Adult Cancer Patients With CDAD In Studies

Optimer Pharmaceuticals, Inc. (OPTR) said Friday that results from a post-hoc subgroup analysis of the company's two large Phase 3 trials showed cancer patients with Clostridium difficile-associated diarrhea had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID tablets compared to oral vancomycin.

The data will be presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases in London.

The analysis included 153 patients with active cancer who were treated in the two DIFICID Phase 3 studies and who received 8 days or more of treatment with DIFICID or oral vancomycin. In the overall combined population, patients with cancer had significantly lower cure and sustained response rates than patients without cancer. DIFICID was five times more likely than vancomycin to produce a clinical response and three times more likely to lead to a sustained response, while patients treated with vancomycin had a 2.6 fold greater risk of experiencing recurrence. Infections caused by C. difficile and the resulting diarrhea pose a significant threat to cancer patients, mainly those with compromised immune systems due to chemotherapy or stem cell transplants.

"The results from this analysis reinforce the important role of DIFICID in the treatment of CDAD, especially its use as a front-line agent," said Sherwood Gorbach, Chief Scientific Officer and Senior Vice President of Optimer. "We are encouraged by these results and look forward to conducting future clinical trials to explore the potential benefits of DIFICID in patients with cancer and others who are at high risk for CDAD."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Courier Corp. (CRRC) announced Wednesday that its Board has reasonably determined that the non-binding, unsolicited proposal from R.R. Donnelley & Sons Company (RRD) to acquire the Company for $23.00 per share in cash or RR Donnelley common stock is reasonably likely to result in a "Superior Proposal"... Diversified electronics maker TE Connectivity Ltd. agreed Wednesday to sell its broadband network solutions or BNS business unit to telecommunications company CommScope Holding Co., Inc. in an all-cash deal valued at about $3 billion. The sale will enable TE to focus on providing leading connectivity and sensor solutions, particularly harsh environment connectivity. Online foreign exchange trading company FXCM Inc (FXCM) on Wednesday announced its decision to forgive about 90% of its clients who incurred negative balances in certain jurisdictions, on January 15 as a result of the Swiss National Bank announcement on that date. FXCM will notify the applicable clients...
comments powered by Disqus
RELATED NEWS
Trade GRPN now with 
Follow RTT